UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 3, 2021



CARDLYTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware (State or other jurisdiction of incorporation or organization) 675 Ponce de Leon Avenue NE, Suite 6000 001-38386

Atlanta Georgia (Address of principal exec e offices, including zip code) (888) 798-5802

26-3039436 (I.R.S. Employer Identification No.) 30308

Check th	ne appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class Common Stock

Trading symbol CDLX

Name of each exchange on which registered
The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On August 3, 2021, Cardlytics, Inc. (the "Company") issued a press release announcing its financial results for the three and six months ended June 30, 2021, as well as information regarding a conference call to discuss these financial results and the Company's recent corporate highlights. The Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

ITEM 7.01 OTHER EVENTS

On August 3, 2021, the Company is also posting a slide presentation on its website, which the Company will reference during the conference call described above.

A copy of the slide presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.2 hereto shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Exhibit	Exhibit Description
99.1	Press release dated August 3, 2021
99.2	Presentation titled "Earnings Presentation Q2 2021"

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Cardlytics, Inc.

Date: August 3, 2021 By:

/s/ Andrew Christiansen
Andrew Christiansen
Chief Financial Officer
(Principal Financial and Accounting Officer)



Cardlytics Announces Second Quarter 2021 Financial Results

Atlanta, GA - August 3, 2021 - Cardlytics, Inc. (NASDAQ: CDLX), a digital advertising platform, today announced financial results for the second quarter ended June 30, 2021. Supplemental information is available on the Investor Relations section of the Cardlytics' website at http://ir.cardlytics.com/.

"While we grew Cardlytics platform billings 111% and adjusted contribution 123% year-over-year, we fell below our guidance. This was driven by us forecasting a faster recovery than was realized due to labor shortage and supply chain challenges in retail, restaurant and travel," said Lynne Laube, CEO & Co-Founder of Cardlytics. "Our core business remains on a very solid foundation and we continue to make significant progress on all of our strategic initiatives, including the integration of Dosh and Bridg."

"We believe we will still be dealing with an uneven recovery in Q3 as each industry we operate in is still working through unique macroeconomic challenges," said Andy Christiansen, CFO of Cardlytics. "We remain very excited about the long-term potential of Cardlytics and continue to make immense progress on our product and technology initiatives."

Second Quarter 2021 Financial Results

- Revenue was \$58.9 million, an increase of 109% year-over-year, compared to \$28.2 million in the second guarter of 2020.
- · Billings, a non-GAAP metric, was \$85.3 million, an increase of 116% year-over-year, compared to \$39.5 million in the second quarter of 2020.
- $Gross\ profit\ was\ \$23.2\ million,\ an\ increase\ of\ 193\%\ year-over-year,\ compared\ to\ \$7.9\ million\ in\ the\ second\ quarter\ of\ 2020.$
- Adjusted contribution, a non-GAAP metric, was \$29.6 million, an increase of 139% year-over-year, compared to \$12.4 million in the second quarter of 2020.
- Net loss attributable to common stockholders was \$(47.3) million, or \$(1.43) per diluted share, based on 33.0 million weighted-average common shares outstanding, compared to a net loss attributable to common stockholders of \$(19.8) million, or \$(0.73) per diluted share, based on 27.1 million weighted-average common shares outstanding in the second quarter of 2020.
- Non-GAAP net loss was \$(12.8) million, or \$(0.39) per diluted share, based on 33.0 million weighted-average common shares outstanding, compared to a non-GAAP net loss of \$(10.2) million, or \$(0.38) per diluted share, based on 27.1 million weighted-average common shares outstanding in the second quarter of 2020.
- Adjusted EBITDA, a non-GAAP metric, was a loss of \$(5.7) million compared to a loss of \$(7.7) million in the second quarter of 2020.

Key Metrics

- Cardlytics MAUs were 167.6 million, an increase of 7%, compared to 157.2 million in the second quarter of 2020.
- Cardlytics ARPU was \$0.34, an increase of 89%, compared to \$0.18 in the second quarter of 2020.
- Bridg ARR was \$12.5 million in the second quarter of 2021.

Definitions of MAUs, ARPU and ARR are included below under the caption "Non-GAAP Measures and Other Performance Metrics."

Third Ouarter 2021 Financial Expectations

Cardlytics anticipates billings, revenue, and adjusted contribution to be in the following ranges (in millions):

	Q3 2021 Guidance
Billings ⁽¹⁾	\$85.0 - \$95.0
Revenue	\$57.0 - \$66.0
Adjusted contribution ⁽²⁾	\$27.0 - \$32.0

- (1) A reconciliation of billings to GAAP revenue on a forward-looking basis is presented below under the heading "Reconciliation of Forecasted GAAP Revenue to Billings."
 (2) A reconciliation of adjusted contribution to GAAP gross profit on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure

Earnings Teleconference Information

Cardlytics will discuss its second quarter 2021 financial results during a teleconference today, August 3, 2021, at 5:00 PM ET / 2:00 PM PT. The conference call can be accessed at (866) 385-4179 (domestic) or (210) 874-7775 (international), conference ID# 3993796. A replay of the conference call will be available through 8:00 PM ET / 5:00 PM PT on August 10, 2021 at (855) 859-2056 (domestic) or (404) 537-3406 (international). The replay passcode is 3993796. The call will also be broadcast simultaneously at http://ir.cardlytics.com/. Following the completion of the call, a recorded replay of the webcast will be available on Cardlytics' website.

About Caudletia

Cardlytics (NASDAQ: CDLX) is a digital advertising platform. We partner with financial institutions to run their banking rewards programs that promote customer loyalty and deepen banking relationships. In turn, we have a secure view into where and when consumers are spending their money. We use these insights to help marketers identify, reach, and influence likely buyers at scale, as well as measure the true sales impact of marketing campaigns. Headquartered in Atlanta, we have offices in London, New York, San Francisco, Austin and Visakhapatnam. In March 2021, we acquired Dosh, a transaction-based advertising platform, and in May 2021 we acquired Bridg, a customer data platform. Learn more at www.cardlytics.com.

Cautionary Language Concerning Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, our financial guidance for the third quarter of 2021, future growth, the integration of Dosh and Bridg, and achievement of long-range goals. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," or variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control.

Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: risks related to the uncertain impacts that COVID-19 may have on our business, financial condition, results of operations; unfavorable conditions in the global economy and the industries that we serve; our quarterly operating results have fluctuated and may continue to vary from period to period; our ability to sustain our revenue growth and billings; risks related to the integration of Dosh and Bridg with our company; risks related to our substantial dependence on JPMorgan Chase Bank, National Association ("Chase"), Bank of America, National Association ("Bank of America,") and a limited number of other financial institution ("FI") partners; the timing of the phased launch of the Cardlytics platform by U.S. Bank; risks related to our ability to maintain relationships with Chase, Wells Fargo and Bank of America; the amount and timing of budgets by marketers, which are affected by budget cycles, economic conditions and other factors, including the impact of the COVID-19 pandemic; our ability to generate sufficient revenue to offset contractual commitments to FIs; our ability to attract new partners, including FI partners, and maintain relationships with bank processors and digital banking providers; our ability to maintain relationships with marketers; our ability to adapt to changes in consumer habits, negotiate fee arrangements with new and existing partners and retailers, and develop and launch new services and features; and other risks detailed in the "Risk Factors" section of our Form 10-Q filed with the Securities and Exchange Commission. Past performance is not necessarily indicative of future results.

The forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Non-GAAP Measures and Other Performance Metrics

To supplement the financial measures presented in our press release and related conference call or webcast in accordance with generally accepted accounting principles in the United States ("GAAP"), we also present the following non-GAAP measures of financial performance: billings, adjusted contribution, adjusted Partner Share and other third party costs, non-GAAP net loss and non-GAAP net loss per share as well as certain other performance metrics, such as monthly active users ("MAUs"), average revenue per user ("ARPU") and annualized recurring revenue ("ARR").

A "non-GAAP financial measure" refers to a numerical measure of our historical or future financial performance or financial position that is included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP in our financial statements. We provide certain non-GAAP measures as additional information relating to our operating results as a complement to results provided in accordance with GAAP. The non-GAAP financial information presented herein should be considered in conjunction with, and not as a substitute for or superior to, the financial information presented in accordance with GAAP and should not be considered a measure of liquidity. There are significant limitations associated with the use of non-GAAP financial measures. Further, these measures may differ from the non-GAAP information, even where similarly titled, used by other companies and therefore should not be used to compare our performance to that of other companies.

We have presented billings, adjusted contribution, adjusted EBITDA, adjusted Partner Share and other third-party costs, non-GAAP net loss per share as non-GAAP financial measures in this press release. Billings represents the gross amount billed to customers and marketers for advertising campaigns in order to generate revenue. Cardlytics platform billings is recognized gross of both Consumer Incentives and Partner Share. Bridg platform billings is the same as Bridg platform GAAP revenue. We define adjusted contribution as a measure by which revenue generated from our marketers exceeds the cost to obtain the purchase data and the digital advertising space from our partners. Adjusted contribution demonstrates how incremental marketing spend on our platform generates incremental amounts to support our sales and marketing, research and development, general and administration and other investments. Adjusted contribution is calculated by taking our total revenue less our Partner Share and other third-party costs exclusive of deferred implementation costs, which is a non-cash cost. Adjusted contribution does not take into account all costs associated with generating revenue from advertising campaigns, including sales and marketing expenses, research and development expenses, general and administrative expenses and other expenses, which we do not take into account all costs associated with generating revenue from advertising campaigns, we define adjusted EBITDA as our net loss before income tax benefit; interest expense, net; depreciation and amortization expenses; stock-based compensation expense; foreign currency (loss) gain; deferred implementation costs; restructuring costs, acquisition and integration costs and change in fair value of contingent consideration. We define adjusted Partner Share and other third-party costs as our Partner Share and other third-party costs excluding non-cash equity expense and amortization of deferred implementation costs; restructuring costs, acquisition and integration costs; amortiz

We believe the use of non-GAAP financial measures, as a supplement to GAAP measures, is useful to investors in that they eliminate items that are either not part of our core operations or do not require a cash outlay, such as stock-based compensation expense. Management uses these non-GAAP financial measures when evaluating operating performance and for internal planning and forecasting purposes. We believe that these non-GAAP financial measures help indicate underlying trends in the business, are important in comparing current results with prior period results and are useful to investors and financial analysts in assessing operating performance.

We define MAUs as targetable customers or accounts that have logged in and visited online or mobile applications containing offers from, opened an email containing offers from, or redeemed an offer from the Cardlytics platform during a monthly period. We then calculate a monthly average of these MAUs for the periods presented. We define ARPU as the total revenue generated in the applicable period calculated in accordance with GAAP, divided by the average number of MAUs in the applicable period. We define ARR as the annualized GAAP revenue of the final month in the period presented for the Bridg platform. ARR should not be considered in isolation from, or as an alternative to, revenue prepared in accordance with GAAP. We believe that ARR is an indicator of the Bridg platform's ability to generate future revenue from existing clients

CARDLYTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Amounts in thousands)

Assert Assert Security Security <th< th=""><th></th><th>June 30, 2021</th><th colspan="4">December 31, 2020</th></th<>		June 30, 2021	December 31, 2020			
世の歌の歌の歌の歌の歌の歌の歌の歌の歌の歌の歌の歌の歌の歌の歌の歌の歌の歌の歌	Assets					
### ### ### ### ### ### ### ### ###	Current assets:					
Accounts recivable net 73,468 18,289 Ober neces despenses and other assess 81,32 5,687 Tool current assess: 81,325 5,687 Tool current assess: 11,005 13,005 Right-of use assess under operating lease, net 11,005 3,005 Right-of use assess under operating lease, net 11,004 10,006 Goodwall flower development cots, net 17,009 1,007 Copublished flower development cots, net 2,017 1,008 Ober long-term assets, net 2,017 1,008 Other long-term assets, net 2,017 1,008 Total assets 3,02 2,02 Total assets 5,02 2,02 Total assets 5,02 2,02 Account albuffilds 4,00 7,52 Account albuffilds 2,00 7,52 Accounted compensation 9,00 7,52 Accounted compensation 2,00 7,52 Accounted compensation 1,00 4,75 Accounted compensation limit 1,00 4,75	Cash and cash equivalents	\$ 250,603	\$ 293,239			
Ober neckvables Consisted 5.812 5.836 Total current assets 33.45 35.857 Long-term assets 33.65 35.855 Long-term sacts 13.05 13.05 Pixpy and equipment, net 11.06 11.06 Intagalibe assets, net 11.06 11.06 Conduit 9.15 6.09 Conduit 9.15 6.09 Cherical development costs, net 2.17 3.78 Ober long-term assets, net 2.17 3.78 Ober long-term lang-term assets, net 2.17 3.78 Ober former term development consister set 2.12 3.78 Total assets 5.27 5.2 7.5 Accurated Lang-term development consister set 2.27 3.2 <td>Restricted cash</td> <td>111</td> <td>110</td>	Restricted cash	111	110			
beyand expenses and other assets 8.13 5.685 Conde current assets 33.656 35.551 Ungern assets 1.13.05 1.3.056 Right of successes under operating lease, set 1.13.05 1.3.056 Right Osse assets under operating lease, set 1.17.05 4.07 Goodwill 7.18.400 7.18.40 Copitalized outward evelopment costs, net 2.137 5.227 5.228 3.278 Ober long-demindentation costs, net 2.137 5.217 1.706 2.02	Accounts receivable, net	73,468	81,249			
Total current assets 38,595 Long-term assets: 13,095 13,865 Property and equipment, net 11,694 10,786 Sight-of-size assets under operating lease, net 137,185 447 Codubull 718,490 ————————————————————————————————————	Other receivables	6,142	5,306			
Long-term asserts 13,085 13,085 13,085 13,085 13,085 13,085 10,764	Prepaid expenses and other assets	8,132	5,687			
Property and equipment, net 13,095 13,085 Right-of-use asset under operating leases, net 11,73 44 Copfulle assets, net 178,480 4-7 Copfuller Service Mevel Optimer Costs, net 19,15 6,299 Deferred milementation costs, net 2,121 3,785 Orber long-term assets, net 2,121 3,785 Oble long-term assets, net 2,121 3,785 Other long-term assets, net 2,121 3,785 Other long-term assets, net 2,121 3,785 Total assets 2,121 3,785 Charge Service Serv	Total current assets	338,456	385,591			
Property and equipment, net 13,095 13,085 Right-of-use asset under operating leases, net 11,73 44 Copfulle assets, net 178,480 4-7 Copfuller Service Mevel Optimer Costs, net 19,15 6,299 Deferred milementation costs, net 2,121 3,785 Orber long-term assets, net 2,121 3,785 Oble long-term assets, net 2,121 3,785 Other long-term assets, net 2,121 3,785 Other long-term assets, net 2,121 3,785 Total assets 2,121 3,785 Charge Service Serv	Long-term assets:					
Right-due assets under operating lesses, net 11,644 10,764 Goodwill 718,459 —4 Copitalized software development costs, net 9,157 6,299 Deferent implementation costs, net 2,173 3,785 Other long-term assets, net 2,173 3,785 Total assets 1,202,000 2,173 3,785 Total sexte 5 1,202,000 2,202,000 3,785 Tabilities 5 1,202,000 7,502 1,786 </td <td></td> <td>13,095</td> <td>13,865</td>		13,095	13,865			
Goodwill 718,490 ————————————————————————————————————	Right-of-use assets under operating leases, net	11,694	10,764			
Goodwill 718,490 ————————————————————————————————————		137.185	447			
befered implementation costs, net 2,137 3,785 Other long-terms assets, net 5 1,232 2 2,232 Total assets	Goodwill	718,490	_			
befered implementation costs, net 2,137 3,785 Other long-terms assets, net 5 1,232 2 2,232 Total assets	Capitalized software development costs, net	9,157	6,299			
Ober long-term assets, net 5, 1,2026 1,786 Total assets 5, 1,2026 2,2025 Libilities and stockholders' equiv Unreal tabilities: Accounts payable 5, 5, 217 5, 1, 205 Accured compensation 9,00 7, 528 Accured expenses 8, 207 9,00 5,502 Accured expenses 8, 207 9,00 5,502 Partner Share liability 2, 207 340 Consumer Incentive liability 6, 207 340 Current operating lease liabilities 6, 207 340 Current operating lease liabilities 1, 207 340 Current contract lease liabilities 1, 207 340 Current contract liabilities 1, 207 340 Current contract liabilities 1, 207 340 Current contract liabilities 1, 207 340 Total carrent liabilities 1, 207 340 Current contract liabilities 1, 207 340 Current contract liabilities 1, 207 340 Cong-term liabi		2,173	3,785			
Tabilities and such bolders' equity Section Sectio		2,617				
Current labilities Current lability Current lability Current lability Current lability Current lability Current lability Current labilities Current labilities		\$ 1,232,867				
Current liabilities: \$	Liabilities and stockholders' equity		=			
Accounts payable \$ 5,217 \$ \$ 1,363 Accounted liabilities: Accounted compensation 9,090 7,582 Accounted expenses 8,207 5,502 Partures Phare Ilability 28,688 37,457 Consumer Incentive liability 36,561 24,290 Deferred revenue 2,277 349 Current operating lease liabilities 6,000 4,718 Current finance lease liabilities 16,455 — Current finance lease liabilities 16,455 — Other current liabilities 1,457 — Total current liabilities 1,457 — Convertible senior notes, net 19,113 174,011 Long-term liabilities 44 — Long-term finance lease liabilities 43 9,381 Long-term integen consideration 67,449 — Long-term integen consideratio						
Accrued Isabilities: Accrued compensation		\$ 5.217	\$ 1.363			
Accrued compensation 9,090 7,582 Accrued expenses 8,207 5,502 Partner Share liability 28,688 37,457 Consumer Incentive liability 36,561 24,290 Deferred revenue 2,777 349 Current operating lease liabilities 6,000 4,718 Current finance lease liabilities 23 13 Current contingent consideration 164,952 — Other current liabilities 26,972 81,274 Long-term liabilities 26,972 81,274 Long-term liabilities 1,457 — Convertible senior notes, net 19,113 174,011 Long-term perating lease liabilities 4 — Conjeterm operating lease liabilities 4 — Conjeterm perating lease liabilities 8,218 9,381 Long-term perating lease liabilities 518,475 679 Total liabilities 518,475 265,345 Stockholders' equity 518,475 265,345 Stockholders' equity 51,429 <		5,217	ψ 1,303			
Accrued expenses 8,207 5,502 Partner Share liability 26,688 37,457 Consumer Incentive liability 36,561 24,290 Deferred revenue 2,777 349 Current operating lease liabilities 6,000 4,718 Current operating lease liabilities 23 13 Current contingent consideration 16,4952 — Other current liabilities 26,2972 81,274 Long-term liabilities 26,2972 81,274 Long-term liabilities 44 — Convertible senior notes, net 44 — Long-term finance lease liabilities 44 — Long-term operating lease liabilities 44 — Long-term finance lease liabilities 67,449 — Long-term consideration 67,449 — Other long-term liabilities 518,475 265,345 Stockholders' equity 518,475 526,345 Current contingent consideration 679 679 Total liabilities 51,429 526,345 <td></td> <td>9.090</td> <td>7 582</td>		9.090	7 582			
Partner Share liability 28,688 37,457 Consumer Incentive liability 36,551 24,209 Deferred revenue 2,777 349 Current operating lease liabilities 6,000 4,718 Current finance lease liabilities 23 13 Current contingent consideration 164,952 — Other current liabilities 1,457 — Total current liabilities 262,972 81,274 Long-term liabilities 179,113 174,011 Long-term liabilities 44 — Long-term operating lease liabilities 8,218 9,381 Long-term operating lease liabilities 8,218 9,381 Long-term contingent consideration 67,49 — Other long-term liabilities 679 679 Total liabilities 518,475 265,345 Stock-bodiers' equity 8 8 Common stock, SO,0001 par value—100,000 shares authorized and 27,861 and 33,023 shares issued and outstanding as of December 31, 2020 and June 30, 22, 22, 22, 22, 22, 22, 22, 22, 22, 2						
Consumer Incentive İlability 36,561 24,290 Defered revenue 2,777 349 Current Operating lease liabilities 6,000 4,718 Current finance lease liabilities 23 13 Current contingent consideration 164,952 — Other current liabilities 1,457 — Total current liabilities 262,972 81,274 Long-term liabilities 179,113 174,011 Convertible senior notes, net 19,113 174,011 Long-term liabilities 4 — Long-term operating lease liabilities 4 — Long-term orinitingent consideration 67,49 — Other long-term liabilities 57,93 679 Total liabilities 679 679 Total liabilities 518,475 265,345 Stockholders' equity 8 8 Additional pail-dai-dail-dail-dail-dail-dail-dail-da						
Deferred revenue 2,777 349 Current operating lease liabilities 6,000 4,718 Current finance lease liabilities 23 13 Current contingent consideration 164,952 Other current liabilities 262,972 81,274 Long-term liabilities: 262,972 81,274 Convertible senior notes, net 179,113 174,011 Long-term finance lease liabilities 4 Long-term contingent consideration 67,449 Other long-term liabilities 67,449 Under the contingent consideration 67,449 Other long-term liabilities 518,475 265,345 Stockholders' equity: 58,00001 par value—100,000 shares authorized and 27,861 and 33,023 shares issued and outstanding as of December 31, 2020 and June 30, 2021, respectively. 8 8 Additional paid-in capital 1,181,290 551,429 Accumulated other comprehensive income (652) (192) Accumulated officit (466,254) (394,053) Total stockholders' equity 714,392 151,						
Current operating lease liabilities 6,000 4,718 Current finance lease liabilities 23 13 Current contingent consideration 164,952 — Other current liabilities 1,457 — Total current liabilities 262,972 81,274 Long-term liabilities 179,113 174,011 Long-term liabilities 179,113 174,011 Long-term finance lease liabilities 44 — Long-term finance lease liabilities 8,218 9,381 Long-term finance lease liabilities 67,449 — Long-term consideration 67,449 — Other long-term liabilities 56,949 — Total liabilities 56,949 — Stockholders' equity — 67,949 — Common stock, S0,0001 par value—100,000 shares authorized and 27,861 and 33,023 shares issued and outstanding as of December 31, 2020 and June 30, 2021, respectively. 8 8 Additional paid-in capital 1,181,290 551,429 Accumulated other comprehensive income (652) (192) Accu						
Current finance lease liabilities 13 Current contingent consideration 164,952 — Other current liabilities 262,972 81,274 Total current liabilities: 526,972 81,274 Long-term liabilities: 179,113 174,011 Convertible senior notes, net 179,113 174,011 Long-term diabilities 8,218 9,381 Long-term contingent consideration 8,218 9,381 Long-term contingent consideration 679 679 Total liabilities 518,475 265,345 Stockholders' equity: 518,475 265,345 Common stock, S0,0001 par value—100,000 shares authorized and 27,861 and 33,023 shares issued and outstanding as of December 31, 2020 and June 30, 2021, respectively. 8 8 Additional paid-in capital 1,181,290 551,429 Accumulated other comprehensive income (652) (192) Accumulated deficit (466,254) (394,053) Total stockholders' equity 714,392 157,929						
Current contingent consideration 164,952 — Other current liabilities 262,972 81,274 Long-term liabilities: 826,972 81,274 Cong-term liabilities: 179,113 174,011 Long-term finance lease liabilities 179,113 174,011 Long-term operating lease liabilities 8,218 9,381 Long-term contingent consideration 67,449 — Other long-term liabilities 679 679 Total labilities 518,475 265,345 Stockholders' equity: 518,475 265,345 Common stock, \$0,0001 par value—100,000 shares authorized and 27,861 and 33,023 shares issued and outstanding as of December 31, 2020 and June 30, 2021, respectively. 8 8 Additional paid-in capital 1,181,290 551,429 Accumulated other comprehensive income (652) (192) Accumulated deficit (394,053) Total stockholders' equity 714,392 157,192						
Other current liabilities 1,457 — Total current liabilities 262,972 81,274 Long-term liabilities 81,274 Convertible senior notes, net 179,113 174,011 Long-term operating lease liabilities 44 — Long-term operating lease liabilities 8,218 9,381 Long-term contingent consideration 67,49 — Other long-term liabilities 518,475 265,345 Stockholders' equity: 518,475 265,345 Common stock, \$0,0001 par value—100,000 shares authorized and 27,861 and 33,023 shares issued and outstanding as of December 31, 2020 and June 30, 2021, respectively. 8 8 Additional paid-in capital 1,181,290 551,429 Accumulated other comprehensive income (652) (192) Accumulated deficit (466,254) (394,053) Total stockholders' equity 714,392 157,192						
Total current liabilities 262,972 81,274 Long-term liabilities: 179,113 174,011 Convertible senior notes, net 179,113 174,011 Long-term finance lease liabilities 4 — Long-term operating lease liabilities 8,218 9,381 Long-term contingent consideration 67,449 — Other long-term liabilities 679 679 Total liabilities 518,475 265,345 Stockholders' equity 8 8 Common stock, S0,0001 par value—100,000 shares authorized and 27,861 and 33,023 shares issued and outstanding as of December 31, 2020 and June 30, 2021, respectively. 8 8 Additional paid-in capital 1,181,290 551,429 Accumulated other comprehensive income (652) (192) Accumulated other comprehensive income (466,254) (394,053) Total stockholders' equity 714,392 157,92						
Long-term liabilities: 179,113 174,011 Convertible senior notes, net 179,113 174,011 Long-term finance lease liabilities 8,218 9,381 Long-term contingent consideration 67,449 — Other long-term liabilities 679 679 Total liabilities 518,475 265,345 Stockholders' equity: 8 8 Common stock, \$0,0001 par value—100,000 shares authorized and 27,861 and 33,023 shares issued and outstanding as of December 31, 2020 and June 30, 2021, respectively. 8 8 Additional paid-in capital 1,181,290 551,429 Accumulated other comprehensive income (652) (192) Accumulated deficit (466,254) (394,053) Total stockholders' equity 714,392 157,192						
Convertible senior notes, net 179,113 174,011 Long-term finance lease liabilities 8,218 9,381 Long-term portaing lease liabilities 67,449 — Other long-term contingent consideration 67,449 — Other long-term liabilities 518,475 265,345 Total liabilities 518,475 265,345 Stockholders' equity: 8 8 Common stock, \$0,0001 par value—100,000 shares authorized and 27,861 and 33,023 shares issued and outstanding as of December 31, 2020 and June 30, 2021, respectively. 8 8 Additional paid-in capital 1,181,290 551,429 Accumulated other comprehensive income (652) (192) Accumulated deficit (466,254) (394,053) Total stockholders' equity 714,392 157,92		202,372	01,274			
Long-term finance lease liabilities 44 — Long-term operating lease liabilities 8,218 9,381 Long-term contingent consideration 67,449 — Other long-term liabilities 518,475 265,345 Total liabilities 518,475 265,345 Stockholders' equity: 8 8 Common stock, \$0,0001 par value—100,000 shares authorized and 27,861 and 33,023 shares issued and outstanding as of December 31, 2020 and June 30, 2021, respectively. 8 8 Additional paid-in capital 1,181,290 551,429 Accumulated other comprehensive income (466,25) (394,053) Accumulated deficit (466,254) (394,053) Total stockholders' equity 714,392 157,192		170 113	174.011			
Long-term operating lease liabilities 8,218 9,381 Long-term contingent consideration 67,449 — Other long-term liabilities 679 679 Total liabilities 518,475 265,345 Stockholders' equity: 8 8 Common stock, \$0,0001 par value—100,000 shares authorized and 27,861 and 33,023 shares issued and outstanding as of December 31, 2020 and June 30, 2021, respectively. 8 8 Additional paid-in capital 1,181,290 551,429 Accumulated other comprehensive income (652) (192) Accumulated deficit (466,254) (394,053) Total stockholders' equity 714,392 157,192						
Long-term contingent consideration 67,449 — Other long-term liabilities 679 679 Total liabilities 518,475 265,345 Stockholders' equity: Common stock, \$0,0001 par value—100,000 shares authorized and 27,861 and 33,023 shares issued and outstanding as of December 31, 2020 and June 30, 2021, respectively. 8 8 Additional paid-in capital 1,181,290 551,429 Accumulated other comprehensive income (652) (192) Accumulated deficit (466,254) (394,053) Total stockholders' equity 714,392 157,192						
Other long-term liabilities 679 679 Total liabilities 518,475 265,345 Stockholders' equity:						
Total liabilities 518,475 265,345 Stockholders' equity:						
Stockholders' equity: Common stock, \$0.0001 par value—100,000 shares authorized and 27,861 and 33,023 shares issued and outstanding as of December 31, 2020 and June 30, 2021, respectively. 8 8 Additional paid-in capital 1,181,290 551,429 Accumulated other comprehensive income (652) (192) Accumulated deficit (466,254) (394,053) Total stockholders' equity 714,392 157,192						
Common stock, \$0.0001 par value—100,000 shares authorized and 27,861 and 33,023 shares issued and outstanding as of December 31, 2020 and June 30, 2021, respectively. 8 8 8 Additional paid-in capital 1,181,290 551,429 Accumulated other comprehensive income (652) (192) Accumulated deficit (466,254) (394,053) Total stockholders' equity 714,392 157,192		518,4/5	265,345			
2021, respectively. 8 Additional paid-in capital 1,181,290 551,429 Accumulated other comprehensive income (652) (192) Accumulated deficit (466,254) (394,053) Total stockholders' equity 714,392 157,192						
Additional paid-in capital 1,181,290 551,429 Accumulated other comprehensive income (652) (192) Accumulated deficit (466,254) (394,053) Total stockholders' equity 714,392 157,192		8	. 8			
Accumulated other comprehensive income (652) (192) Accumulated deficit (466,254) (394,053) Total stockholders' equity 714,392 157,192						
Accumulated deficit (466,254) (394,053) Total stockholders' equity 714,392 157,192						
Total stockholders' equity 714,392 157,192						
	• •					

CARDLYTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Amounts in thousands, except per share amounts)

			nths Ended e 30,		ths Ended e 30,
		2021	2020	2021	2020
Revenue	\$	58,853	\$ 28,222	\$ 112,083	\$ 73,731
Costs and expenses:					
Partner Share and other third-party costs		29,953	16,811	59,724	42,949
Delivery costs		5,748	3,499	9,686	6,905
Sales and marketing expense		17,063	10,405	30,265	21,373
Research and development expense		8,934	3,966	15,152	7,817
General and administration expense		16,888	11,734	29,063	22,478
Acquisition and integration costs		14,182	_	21,212	_
Depreciation and amortization expense		8,833	1,545	11,898	3,876
Total costs and expenses		101,601	47,960	177,000	105,398
Operating loss		(42,748)	(19,738)	(64,917)	(31,667)
Other income (expense):					
Interest (expense) income, net		(3,078)	(10)	(6,123)	274
Change in fair value of contingent consideration		(1,480)	_	(1,480)	_
Foreign currency (loss) gain		_	(10)	319	(1,896)
Total other expense	-	(4,558)	(20)	(7,284)	(1,622)
Loss before income taxes		(47,306)	(19,758)	(72,201)	(33,289)
Income tax benefit			· -	<u> </u>	
Net loss		(47,306)	(19,758)	(72,201)	(33,289)
Net loss attributable to common stockholders	\$	(47,306)	\$ (19,758)	\$ (72,201)	\$ (33,289)
Net loss per share attributable to common stockholders, basic and diluted	\$	(1.43)	\$ (0.73)	\$ (2.32)	\$ (1.24)
Weighted-average common shares outstanding, basic and diluted		32,977	27,072	31,145	26,898

CARDLYTICS, INC. STOCK-BASED COMPENSATION EXPENSE (UNAUDITED) (Amounts in thousands)

		Three Mor Jun	nths l e 30,		Six Months Ended June 30,				
	2	021		2020		2021		2020	
Delivery costs	\$	521	\$	357	\$	830	\$	532	
Sales and marketing expense		3,655		2,567		6,087		3,836	
Research and development expense		2,448		1,401		3,962		2,004	
General and administrative expense		6,713		4,783		9,706		6,861	
Total stock-based compensation expense	\$	13,337	\$	9,108	\$	20,585	\$	13,233	

CARDLYTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (Amounts in thousands)

	s	ix Month	
	2021		2020
Operating activities			
Net loss	\$ (7	72,201)	\$ (33,289)
Adjustments to reconcile net loss to net cash used in operating activities:			
Credit loss expense		1,156	1,326
Depreciation and amortization		11,898	3,876
Amortization of financing costs charged to interest expense		448	48
Accretion of debt discount and non-cash interest expense		4,680	_
Amortization of right-of-use assets		2,354	1,731
Stock-based compensation expense		20,585	13,233
Change in fair value of contingent consideration		1,480	_
Other non-cash expense, net		(279)	2,073
Amortization of deferred implementation costs		1,612	1,999
Change in operating assets and liabilities:			
Accounts receivable		10,209	42,460
Prepaid expenses and other assets		(1,896)	(603)
Accounts payable		2,021	(163)
Other accrued expenses		2,021	(6,922)
Partner Share liability		(8,768)	(22,665)
Consumer Incentive liability		(2,830)	(10,748)
Net cash used in operating activities	(2	27,510)	(7,644)
Investing activities			```
Acquisition of property and equipment		(1,790)	(1,225)
Acquisition of patents		(58)	(30)
Capitalized software development costs		(4,431)	(2,132)
Business acquisition, net of cash acquired	(49	94,131)	_
Net cash used in investing activities		00,410)	(3,387)
Financing activities	· ·		()
Principal payments of debt		(11)	(11)
Proceeds from issuance of common stock	4	35,690	5,435
Deferred equity issuance costs		(190)	
Debt issuance costs		(86)	(13)
Net cash received from financing activities	4	35,403	5,411
Effect of exchange rates on cash, cash equivalents and restricted cash		(118)	(492)
Net increase in cash, cash equivalents and restricted cash		12,635)	(6,112)
Cash, cash equivalents, and restricted cash — Beginning of period		93,349	104,587
Cash, cash equivalents, and restricted cash — End of period			\$ 98,475
Casn, casn equivalents, and restricted casn — End of period	\$ 2.	10,714	90,473

CARDLYTICS, INC. SUMMARY OF GAAP AND NON-GAAP RESULTS (UNAUDITED) (Dollars in thousands)

		Mont June	hs Ended 30,	Ch	ange	Six Mont Jun	hs E e 30,			Change			
	2021		2020	\$	%	2021		2020		\$	%		
Billings ⁽¹⁾	\$ 85,3	37	\$ 39,521	\$ 45,816	116 %	\$ 161,654	\$	107,297	\$	54,357	51 %		
Consumer Incentives	26,4	34	11,299	15,185	134	49,571		33,566		16,005	48		
Revenue	58,8	53	28,222	30,631	109	112,083		73,731		38,352	52		
Adjusted Partner Share and other third-party costs ⁽¹⁾	29,2	23	15,820	13,403	85	58,112		40,950	_	17,162	42		
Adjusted contribution ⁽¹⁾	29,6	30	12,402	17,228	139	53,971		32,781		21,190	65		
Delivery costs	5,7	48	3,499	2,249	64	9,686		6,905		2,781	40		
Deferred implementation costs	7	30	991	(261)	(26)	1,612		1,999		(387)	(19)		
Gross profit	\$ 23,1	52	\$ 7,912	\$ 15,240	193 %	\$ 42,673	\$	23,877	\$	18,796	79 %		
Net loss	\$ (47,3)	06)	\$ (19,758)	\$ (27,548)	139 %	\$ (72,201)	\$	(33,289)	\$	(38,912)	117 %		
Adjusted EBITDA ⁽¹⁾	\$ (5,6)	66)	\$ (7,693)	\$ 2,027	(26)%	\$ (9,610)	\$	(11,676)	\$	2,066	(18)%		

⁽¹⁾ Billings, adjusted Partner Share and other third-party costs, adjusted contribution and adjusted EBITDA are non-GAAP measures. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are presented below under the headings "Reconciliation of GAAP Revenue to Billings", "Reconciliation of GAAP Gross Profit to Adjusted Contribution" and "Reconciliation of GAAP Net Loss to Adjusted EBITDA."

CARDLYTICS, INC. RECONCILIATION OF GAAP REVENUE TO BILLINGS (UNAUDITED) (Amounts in thousands)

	7	Three Months Ended June 30, 2021				Six Months Ended June 30, 2021								
Cardlytics Platform		Bridg Platform		Consolidated	Cardlytics Platform			Bridg Platform		Consolidated				
\$ 56,763	\$	2,090	\$	58,853	\$	109,993	\$	2,090	\$	112,083				
26,484		_		26,484		49,571				49,571				
\$ 83,247	\$	2,090	\$	85,337	\$	159,564	\$	2,090	\$	161,654				
	\$ 56,763 26,484	Cardlytics Platform \$ 56,763 \$ 26,484	Cardlytics Platform Bridg Platform \$ 56,763 \$ 2,090 26,484	June 30, 2021 Cardlytics Platform Bridg Platform \$ 56,763 \$ 2,090 \$	June 30, 2021 Cardlytics Platform Bridg Platform Consolidated 56,763 2,090 58,853 26,484 26,484	June 30, 2021 Cardlytics Platform Bridg Platform Consolidated \$ 56,763 \$ 2,090 \$ 58,853 26,484 — 26,484	June 30, 2021 Cardlytics Platform Bridg Platform Consolidated Cardlytics Platform \$ 56,763 \$ 2,099 \$ 58,853 \$ 109,993 26,484 — 26,484 49,571	June 30, 2021 Cardlytics Platform Bridg Platform Consolidated Cardlytics Platform \$ 56,763 \$ 2,090 \$ 58,853 \$ 109,993 \$ 26,484 — 26,484 49,571	June 30, 2021 Cardlytics Platform Bridg Platform Consolidated Cardlytics Platform Bridg Platform \$ 56,763 \$ 2,090 \$ 58,853 \$ 109,993 \$ 2,090 26,484 49,571	June 30, 2021 Cardlytics Platform Bridg Platform Consolidated Cardlytics Platform Bridg Platform \$ 56,763 \$ 2,090 \$ 58,853 109,993 \$ 2,090 \$ \$ 26,484 49,571 - 26,484 49,571 -				

		-	Three Months Ended June 30, 2020				Six Months Ended June 30, 2020								
	Cardlytics Platform	Bridg Platform			Consolidated	Cardlytics Platform			Bridg Platform		Consolidated				
Revenue	\$ 28,222	\$	_	\$	28,222	\$	73,731	\$		\$	73,731				
Plus:															
Consumer Incentives	11,299		_		11,299		33,566		_		33,566				
Billings	\$ 39,521	\$	_	\$	39,521	\$	107,297	\$	_	\$	107,297				

CARDLYTICS, INC. RECONCILIATION OF GAAP GROSS PROFIT TO ADJUSTED CONTRIBUTION (UNAUDITED) (Amounts in thousands) Three Months Ended

		Th	ree Months Ended June 30, 2021			Six Months Ended June 30, 2021								
Cardlyti	cs Platform	I	Bridg Platform		Consolidated	Cardlytics P	latform	Bridg Platform		Consolidated				
\$	56,763	\$	2,090	\$	58,853	\$	109,993	\$ 2,090	\$	112,083				
	29,890		63		29,953		59,661	63		59,724				
	4,837		911		5,748		8,775	911		9,686				
	22,036		1,116		23,152		41,557	1,116		42,673				
	4,837		911		5,748		8,775	911		9,686				
	730		_		730		1,612	_		1,612				
\$	27,603	\$	2,027	\$	29,630	\$	51,944	\$ 2,027	\$	53,971				
	Cardlytis \$	29,890 4,837 22,036 4,837 730	Cardlytics Platform I \$ 56,763 \$ 29,890 4,837 22,036 4,837 730 730	Cardlytics Platform Bridg Platform \$ 56,763 \$ 2,090 29,890 63 4,837 911 22,036 1,116 4,837 911 730 —	Sample S	June 30, 2021 Cardlytics Platform Bridg Platform Consolidated \$ 56,763 \$ 2,090 \$ 58,853 29,890 63 29,953 4,837 911 5,748 22,036 1,116 23,152 4,837 911 5,748 730 — 730	Sample S	Cardlytics Platform Bridg Platform Consolidated Cardlytics Platform \$ 56,763 \$ 2,090 \$ 58,853 \$ 109,993 29,890 63 29,953 59,661 4,837 911 5,748 8,775 22,036 1,116 23,152 41,557 4,837 911 5,748 8,775 730 730 1,612	Cardlytics Platform Bridg Platform Consolidated Cardlytics Platform Bridg Platform \$ 56,763 \$ 2,090 \$ 58,853 \$ 109,993 \$ 2,090 29,890 63 29,953 59,661 63 4,837 911 5,748 8,775 911 22,036 1,116 23,152 41,557 1,116 4,837 911 5,748 8,775 911 730 - 730 1,612 -	Cardlytics Platform Bridg Platform Consolidated Cardlytics Platform Bridg Platform Bridg Platform Stage Platform Bridg Platform Stage Platform Stage Platform Bridg Platform Stage Platform <th< td=""></th<>				

- (1) Stock-based compensation expense recognized in consolidated delivery costs totaled \$0.5 million and \$0.8 million for the three and six months ended June 30, 2021, respectively.
 (2) Deferred implementation costs is excluded from adjusted Partner Share and other third-party costs as follows (in thousands):

			7	Three Months Ended June 30, 2021		Six Months Ended June 30, 2021							
	Cardlyt	ics Platform		Bridg Platform	Consolidated	Cardlytics Platform			Bridg Platform		Consolidated		
Partner Share and other third-party costs	\$	29,890	\$	63	\$ 29,953	\$	59,661	\$	63	\$	59,724		
Minus:													
Deferred implementation costs		730		_	730		1,612		_		1,612		
Adjusted Partner Share and other third-party costs	\$	29,160	\$	63	\$ 29,223	\$	58,049	\$	63	\$	58,112		

CARDLYTICS, INC.

RECONCILIATION OF GAAP GROSS PROFIT TO ADJUSTED CONTRIBUTION (UNAUDITED) (Amounts in thousands)

Three Months Ended June 30, 2020 Six Months Ended June 30, 2020 Cardlytics Platform **Bridg Platform** Consolidated Cardlytics Platform **Bridg Platform** Consolidated 28,222 \$ 28,222 \$ 73,731 Revenue Minus: Partner Share and other third-party costs 16,811 16,811 42,949 42,949 Delivery costs⁽¹⁾ 3,499 3,499 6,905 6,905 Gross profit 7,912 7,912 23,877 Plus: Delivery costs⁽¹⁾ 3,499 3,499 6,905 6,905 Deferred implementation costs⁽²⁾ 991 991 1,999 1,999 12,402 12,402 32,781 Adjusted contribution 32,781

- (1) Stock-based compensation expense recognized in consolidated delivery costs totaled \$0.4 million and \$0.5 million for the three and six months ended June 30, 2020, respectively.
 (2) Deferred implementation costs is excluded from adjusted Partner Share and other third-party costs as follows (in thousands):

			Т	Three Months Ended June 30, 2020			Six Months Ended June 30, 2020					
	Cardlytics Platform		Bridg Platform		Consolidated		Cardlytics Platform		Bridg Platform			Consolidated
Partner Share and other third-party costs	\$	16,811	\$	_	\$	16,811	\$	42,949	\$		\$	42,949
Minus:												
Deferred implementation costs		991		_		991		1,999		_		1,999
Adjusted Partner Share and other third-party costs	\$	15,820	\$		\$	15,820	\$	40,950	\$	=	\$	40,950

CARDLYTICS, INC. RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA (UNAUDITED) (Amounts in thousands)

Three Months Ended June 30, 2021 Bridg Platform Six Months Ended June 30, 2021 Bridg Platform Cardlytics Platform Consolidated Cardlytics Platform Consolidated Net loss (45,328) \$ (1,978) \$ (47,306) \$ (70,223) \$ (1,978) \$ (72,201) 3,078 7,092 3,078 8,833 6,123 10,157 6,123 11,898 Interest expense, net Depreciation and amortization expense 1,741 1,741 Stock-based compensation expense 13,179 158 13,337 20,427 158 20,585 Foreign currency gain
Deferred implementation costs (319) 1,612 21,144 (319) 1,612 21,212 730 730 Acquisition and integration costs
Change in fair value of contingent consideration 14,114 14,182 68 68 1,480 1,480 1,480 1,480 Adjusted EBITDA (5,655) (11) (5,666) (9,599) (11) \$ (9,610)

		Three Months Ended June 30, 2020						Six Months Ended June 30, 2020					
	Cardl	Cardlytics Platform		Bridg Platform		Consolidated	Cardlytics Platform	Bridg Platform		Consolidated			
Net loss	\$	(19,758)	\$		\$	(19,758)	\$ (33,289)	\$	\$	(33,289)			
Plus:													
Interest expense (income), net		10		_		10	(274)	_		(274)			
Depreciation and amortization expense		1,545		_		1,545	3,876	_		3,876			
Stock-based compensation expense		9,108		_		9,108	13,233	_		13,233			
Foreign currency loss		8		_		8	1,894	_		1,894			
Deferred implementation costs		991		_		991	1,999	_		1,999			
Restructuring costs		403		_		403	885	_		885			
Adjusted EBITDA	\$	(7,693)	\$	_	\$	(7,693)	\$ (11,676)	\$	\$	(11,676)			

CARDLYTICS, INC. RECONCILIATION OF GAAP NET LOSS TO NON-GAAP NET LOSS AND NON-GAAP NET LOSS PER SHARE (UNAUDITED) (Amounts in thousands, except per share amounts)

	Three Months Ended June 30,				Six Months Ended June 30,			
		2021	2020		2021		2020	
Net loss	\$	(47,306)	\$ (19,758)	\$	(72,201)	\$	(33,289)	
Plus:								
Stock-based compensation expense		13,337	9,108		20,585		13,233	
Foreign currency loss (gain)		_	8		(319)		1,894	
Acquisition and integration costs		14,182	_		21,212		_	
Amortization of acquired intangibles		5,522	_		6,511		_	
Change in fair value of contingent consideration		1,480	_		1,480		_	
Restructuring costs		_	403		_		885	
Non-GAAP net loss	\$	(12,785)	\$ (10,239)	\$	(22,732)	\$	(17,277)	
Weighted-average number of shares of common stock used in computing non-GAAP net loss per share:								
GAAP weighted-average common shares outstanding, diluted		32,977	27,072		31,145		26,898	
Non-GAAP net loss per share attributable to common stockholders, diluted	\$	(0.39)	\$ (0.38)	\$	(0.73)	\$	(0.64)	

CARDLYTICS, INC. RECONCILIATION OF FORECASTED GAAP REVENUE TO BILLINGS (UNAUDITED) (Amounts in thousands)

	Q3 2021 Guidance
Revenue	\$57.0 - \$66.0
Plus:	
Consumer Incentives	\$28.0 - \$29.0
Billings	\$85.0 - \$95.0

Contacts:

Public Relations: Angie Amberg Cardlytics, Inc. aamberg@cardlytics.com

Investor Relations: Robert Robinson Corporate Development & IR (256) 653-2097 ir@cardlytics.com

William Maina ICR, Inc. (646) 277-1236 ir@cardlytics.com






Disclaimer

This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding expectations about future financial performance or results of Cardlytics, Inc. (*Cardlytics, **ve, **us, **or *ou*) including our financial guidance for the three months ending September 30, 2021, the potential benefits of our scquisitions of Dosh and Bridg, the anticipated impact of our strategic initiatives to create shareholder value, growth in MAUs and ARPU are forward looking statements. The future events and trends discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. The future events are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: risks related to use risks related to use risks related to use risks related to use related to a number of factors, including the inspect of the control of the properties of th

In addition to U.S. GAAP financial information, this presentation includes billings, adjusted contribution, adjusted Partner Share and other third-party costs, adjusted EBITDA, adjusted EBITDA margin, non-GAAP net loss per share, each of which is a non-GAAP financial measure. These non-GAAP financial measures are in addition to, and not a substitute for or superior to, measures of financial performance prepared in accordance with U.S. GAAP. Reconciliations of billings, adjusted contributions and other third-party costs, adjusted EBITDA margin, non-GAAP net loss and non-GAAP net loss per share to the most directly comparable GAAP measures of inadiction in the appendix to this presentation. Please see appendix for referibilisms.





Cardlytics provides a scaled solution based on purchase intelligence



>167M Monthly Active Users(1)



>\$3.6T in Annual Spend⁽²⁾



1 IN 2 U.S. Purchase Transactions(3) **Distinctive Benefits** for Marketers

Reach valuable banking customers

Operate in a brand-safe, privacy-protected, trusted digital channel

Market to the most valuable customers based on their actual spending

Drive in-store and online traffic

Closed-loop solution measures marketing results to the penny



Cardlytics is focused on five strategic initiatives to create shareholder value

Drive long-term growth & operatin leverage	Gontinued expansion of MAUs and advertising budgets while realizing the value of our operating investments
2 Self-service portal	Provide a solution for SMBs and agencies
3 Grocery & CPG at scale	Scaled SKU-level offers from leading brands with a friction-free customer experience
Product & category offers	Product-level offers across wider retail to provide advertisers enhanced flexibility and optionality
5 Next gen customer experience	Upgraded UI / UX for more content and better offer constructs and engagement solutions to drive engagement and spend




Dosh Overview

DO\$H | Founded in 2016 | Headquartered in Austin, TX

Converting high-value customers on behalf of new advertiser and fintech partners while helping more consumers save money

Innovative Platform	 Dosh's technology complements Cardlytics' product and technology roadmap Modern, efficient platform that can quickly integrate with neo-banks, fintechs, smaller banks, and consumer-facing organizations
Partnerships with Long-Term Potential	Dosh brings partnerships with multiple neo-banks and fintech players, including Venmo, Betterment and Ellevest Increased exposure with millennial and younger consumer audiences
New Advertising Solutions	Potential to enable new content desired by existing partners, such as travel and local offers Unique ways for advertisers to connect directly with consumers
Customer Engagement	A test and learn DTC app to better understand engagement and drive advertiser ROI Results utilized by partners to drive faster scaled deployments





Bridg Overview

Bridg | Founded in 2010 | Headquartered in Los Angeles, CA

A customer data platform working with leading retailers to help them understand and reach customers using product-level insights

Product-level Insights that Differentiate from CDP Peers	 Access to SKU and UPC data through its client relationships Connects to all of a merchant's customers point-of-sale through proprietary technology Capable of connecting to most point of sale systems in the U.S. Ability to ingest, clean and categorize SKU data to create usable insights
Partnerships with Leading Businesses	Strong relationships in the restaurant vertical Expansion into retail and grocery with several key contracts signed in 2020 and 2021
Potential New Advertising Solutions	Ability to target on other digital media platforms, including Cardlytics Potential to enable product-level offers for partners Once integrated, Bridg could move to deterministic modeling Possibility for measurement business
Privacy Focused	 Built from the ground up to protect consumer privacy and security Not reliant on cookies or other sources for data ingestion Data never leaves the platform and is never sold



Financial Information & Operating Metrics

悔


Trended Consolidated Results



(t) Adjusted contribution and billings are non-GAAP measures. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are included in the account to this presentation, as well as the definitions of these non-GAAP measures.


© 2021 Cardlytics

Billings and Adjusted Contribution best reflect performance



© 2021 Cardlytics

Q2 2021 year-over-year Consolidated Results



	Three Months Ended June 30		Char	nge		
	2020	2021	\$	%		
Billings ⁽¹⁾	\$39,521	\$85,337	\$45,816	115.9%		
Consumer Incentives	11,299	26,484	15,185	134.4%		
Revenue	\$28,222	\$58,853	\$30,631	108.5%		
Adjusted Partner Share and other third-party costs ⁽¹⁾	15,820	29,223	13,403	84.7%		
Adjusted contribution ^(t)	\$12,402	\$29,630	\$17,228	138.9%		
Delivery costs	3,499	5,748	2,249	64.3%		
Deferred implementation costs	991	730	(261)	(26.3%)		
Gross profit	\$7,912	\$23,152	\$15,240	192.6%		
Net loss	(\$19,758)	(\$47,306)	(\$27,548)	139.4%		
Adjusted EBITDA ⁽¹⁾	(\$7,693)	(\$5,666)	\$2,027	(26.3%)		
	0.0					

1) Billing, adjusted Partner Share and other third-party costs, adjusted contribution and adjusted EBTDA are non-GAAP measures. Reconcilitations of these non-GAAP measures to the most comparable GAAP measures are presented below under the headings. "Reconcilitation of GAAP Revenue to tillings", "Reconciliation of GAAP Gross Profit to Adjusted




Cardlytics Platform Advertiser Spend by Industry

	% Ch	ange	% of Total Advertiser Spend						
		nths Ended O, 2021	Three Months Ended June 30,						
Industry	vs 2020	vs 2019	2019	2020	2021				
Grocery & Gas	> 470%	> (25)%	< 10%	> 0%	> 5%				
Restaurant	> 110%	> 30%	> 25%	> 30%	< 35%				
Retail	> 120%	> 10%	< 30%	< 30%	< 30%				
Travel & Entertainment	> 515%	> (75)%	> 20%	> 0%	< 5%				
Direct to Consumer	> 65%	> 120%	< 15%	> 35%	< 30%				



Cardlytics Platform Engagement Metrics - U.S.

There may be variation in future quarters due to factors such as global economic events, bank launches, new advertisers with significant spend, and growth in nascent or new verticals.



Monthly log-in days(1) show that MAUs are logging in 10.3 and 10.8 days per month on average for Q2 2020 and Q2 2021, respectively. $\textbf{Offer activation rates} \ (\textbf{n}) \ \text{show higher rates for small-ticket, volume-heavy offers versus large-ticket and subscription offers. }$ $\textbf{Campaign spend ratios}^{(1)} \text{ show Cardlytics currently targets a small proportion of total MAU spend.}$

- As budgets increase and more advertisers come onto the platform, more spend from MAUs can be targeted with offers.
 There remains considerable room to target larger audiences in light of existing MAU engagement levels.



Significant MAU increase precedes opportunity for expected Billings growth and future ARPU expansion for the Cardlytics platform



© 2021 Cardlytics



Q2 2021 Results

(Amounts in thousands, except APPL), MALI's and ner share amounts

	Three Months Ended June 30,		inge			Chi	inge	
2021	2020	AMT	%	2021	2020	AMT	%	
\$58,853	\$28,222	\$30,631	108.5%	\$112,083	\$73,731	\$38,352	52.0%	
85,337	39,521	45,816	115.9%	161,654	107,297	54,357	50.7%	
23,152	7,912	15,240	192.6%	42,673	23,877	18,796	78.7%	
29,630	12,402	17,228	138.9%	53,971	32,781	21,190	64.6%	
(47,306)	(19,758)	(27,548)	139.4%	(72,201)	(33,289)	(38,912)	116.9%	
(\$1.43)	(\$0.73)	(\$0.70)	95.9%	(\$2.32)	(\$1.24)	(\$1.08)	87.1%	
(\$5,666)	(\$7,693)	\$2,027	(26.3%)	(\$9,610)	(\$11,676)	\$2,066	(17.7%)	
(9.6%)	(27.3%)	17.6%	(64.7%)	(8.6%)	(15.8%)	7.3%	(45.9%)	
(\$12,785)	(\$10,239)	(\$2,546)	24.9%	(\$22,732)	(\$17,277)	(\$5,455)	31.6%	
(\$0.39)	(\$0.38)	(\$0.01)	2.6%	(\$0.73)	(\$0.64)	(\$0.09)	14.1%	
167.6	157.2	10.4	6.6%	167.9	149.0	18.9	12.7%	
\$0.34	\$0.18	\$0.16	88.9%	\$0.66	\$0.49	\$0.17	33.4%	
\$12,511	\$ -	\$12,511	NM	\$12,511	\$ -	\$12,511	NM	
	958,855 85,855 85,337 23,552 29,630 (47,306) (\$1,43) (\$5,666) (9,6%) (\$0,278) (\$0,39)	Sum SUm	Sun 30, Che	Sum Sum	Sum SUM	Num 10/2 Sum 10/2	Norm 10	

(t) Billings, adjusted contribution, adjusted EBITDA, adjusted EBITDA margin, non-GAAP net loss and non-GAAP net loss per share are non-GAAP measures. Reconciliations of these non-GAAP measures to the mos comparable GAAP measures are included in this appendix to this presentation, as well as definitions of these non-GAAP terms.

(2) Adjusted EBITDA margin is calculated as adjusted EBITDA divided by revenue.



Guidance

(Amounts in millions

	Q3 2021 Guidance
Billings ⁽¹⁾	\$85.0 - \$95.0
Revenue	\$57.0 - \$66.0
Adjusted Contribution ⁽¹⁾	\$27.0 - \$32.0

(f) Billings and adjusted contribution are non-GAAP measures. Definitions of these non-GAAP measures are included in the appendix to this presentation, reconciliation of billings to GAAP reviews on a forward-looking basis is presented below under the heading "Reconciliation of Forecasted GAAP reviews or the standard of the presentation of Forecasted GAAP reviews or the standard of the presentation of Forecasted GAAP reviews or the standard of the presentation of Forecasted GAAP reviews or the standard of the presentation


Reconcilation of GAAP Revenue to Billings

(Amounts in thousands)

	Three Months Ended										
	Mar 31, 2019	Jun 30, 2019	Sept 30, 2019	Dec 31, 2019	Mar 31, 2020	Jun 30, 2020	Sept 30, 2020	Dec 31, 2020	Mar 31, 2021	Jun 30, 2021	
Cardlytics Platform					0			,;;			
Revenue	\$35,988	\$48,730	\$56,419	\$69,293	\$45,509	\$28,222	\$46,079	\$67,082	\$53,230	\$56,763	
Plus:											
Consumer Incentives	22,562	25,046	26,373	31,642	22,267	11,299	16,014	26,883	23,087	26,484	
Billings	\$58,550	\$73,776	\$82,792	\$100,935	\$67,776	\$39,521	\$62,093	\$93,965	\$76,317	\$83,247	
Bridg Platform											
Revenue	-	*5	-		1.7			-	- 1	\$2,090	
Plus:											
Consumer Incentives		-		-	-	-	-	-			
Billings	-	-	-	-	-	-		-		\$2,090	
Consolidated											
Revenue	\$35,988	\$48,730	\$56,419	\$69,293	\$45,509	\$28,222	\$46,079	\$67,082	\$53,230	\$58,853	
Plus:											
Consumer Incentives	22,562	25,046	26,373	31,642	22,267	11,299	16,014	26,883	23,087	26,484	
Billings	\$58,550	\$73,776	\$82,792	\$100,935	\$67,776	\$39,521	\$62,093	\$93,965	\$76,317	\$85,337	



Reconciliation of GAAP Gross Profit to Adjusted Contribution

(Amounts in thousand

		Three Months Ended								
Cardlytics Platform	Mar 31, 2019	Jun 30, 2019	Sept 30, 2019	Dec 31, 2019	Mar 31, 2020	Jun 30, 2020	Sept 30, 2020	Dec 31, 2020	Mar 31, 2021	Jun 30, 2021
Revenue	\$35,988	\$48,730	\$56,419	\$69,293	\$45,509	\$28,222	\$46,079	\$67,082	\$53,230	\$56,763
Minus:										
Partner Share and other third-party costs	19,004	27,620	32,470	38,986	26,138	16,811	27,971	38,388	29,771	29,890
Delivery costs	3,246	3,370	3,070	3,207	3,406	3,499	3,498	3,907	3,938	4,837
Gross Profit	\$13,738	\$17,740	\$20,879	\$27,100	\$15,965	\$7,912	\$14,610	\$24,787	\$19,521	\$22,036
Plus:										
Delivery costs	3,246	3,370	3,070	3,207	3,406	3,499	3,498	3,907	3,938	4,837
Deferred implementation costs	653	731	789	696	1,008	991	1,641	958	882	730
Adjusted contribution	\$17,637	\$21,841	\$24,738	\$31,003	\$20,379	\$12,402	\$19,749	\$29,652	\$24,341	\$27,603
Bridg Platform										
Revenue										\$2,090
Ainus:										
Partner Share and other third-party costs										63
Delivery costs										911
Gross Profit				e .		8				\$1,116
Plus:										
Delivery costs	_ 4	- 2		- 2	_				200	911
Adjusted contribution			-		(90)	_	-		-	\$2,027
Consolidated										
Revenue	\$35,988	\$48,730	\$56,419	\$69,293	\$45,509	\$28,222	\$46,079	\$67,082	\$53,230	\$58,853
Ainus:										
Partner Share and other third-party costs	19,004	27,620	32,470	38,986	26,138	16,811	27,971	38,388	29,771	29,963
Delivery costs	3,246	3,370	3,070	3,207	3,406	3,499	3,498	3,907	3,938	5,748
Gross Profit	\$13,738	\$17,740	\$20,879	\$27,100	\$15,965	\$7,912	\$14,610	\$24,787	\$19,521	\$23,152
Mus:										
Delivery costs	3,246	3,370	3,070	3,207	3,406	3,499	3,498	3,907	3,938	5,748
Deferred implementation costs	653	731	789	696	1,008	991	1,641	958	882	730
Adjusted contribution	\$17,637	\$21,841	\$24,738	\$31,003	\$20,379	\$12,402	\$19,749	\$29,652	\$24,341	\$29,630



Reconciliation of GAAP Partner Share and Other Third-Party Costs to Adjusted Partner Share and Other Third-Party Costs

(Amounts in thousands

	Three Months Ended									
Cardlytics Platform	Mar 31, 2019	Jun 30, 2019	Sept 30, 2019	Dec 31, 2019	Mar 31, 2020	Jun 30, 2020	Sept 30, 2020	Dec 31, 2020	Mar 31, 2021	Jun 30, 2021
Partner Share and other third-party costs	\$19,004	\$27,620	\$32,470	\$38,986	\$26,138	\$16,811	\$27,971	\$38,388	\$29,771	\$29,890
Minus:										
Deferred implementation costs	653	731	789	696	1,008	991	1,641	958	882	730
Adjusted Partner Share and other third-party costs	\$18,351	\$26,889	\$31,681	\$38,290	\$25,130	\$15,820	\$26,330	\$37,430	\$28,889	\$29,160
Bridg Platform										
Partner Share and other third-party costs		-		-	-		-	-	-	\$63
Minus:										
Deferred implementation costs		-	-		197		-	-	-	-
Adjusted Partner Share and other third-party costs		-	-		-	-	0	9	(4)	\$63
Consolidated										
Partner Share and other third-party costs	\$19,004	\$27,620	\$32,470	\$38,986	\$26,138	\$16,811	\$27,971	\$38,388	\$29,771	\$29,953
Minus:										
Deferred implementation costs	653	731	789	696	1,008	991	1,641	958	882	730
Adjusted Partner Share and other third-party costs	\$18,351	\$26,889	\$31,681	\$38,290	\$25,130	\$15,820	\$26,330	\$37,430	\$28,889	\$29,223



Reconcilation of GAAP Net (Loss) Income to Adjusted EBITDA

(Amounts in thousand

		Three Months Ended									
Cardivtics Platform	Mar 31, 2019	Jun 30, 2019	Sept 30, 2019	Dec 31, 2019	Mar 31, 2020	Jun 30, 2020	Sept 30, 2020	Dec 31, 2020	Mar 31, 2021	Jun 30, 2021	
Net (loss) income	(\$6,314)	(\$6,510)	(\$7,747)	\$3,427	(\$13,531)	(\$19,758)	(\$15,356)	(\$6,777)	(\$24,895)	(\$45,328)	
Musi											
Income tax benefit											
Interest expense (income), net	304	338	218	(312)	(284)	10	283	3,039	3,045	3,078	
Depreciation and amortization expense	961	1,053	1,167	1,354	2,331	1,545	1,933	2,017	3,065	7,092	
Stock-based compensation expense	1,708	3,072	7,486	3,585	4,126	9,108	11,578	7,584	7,248	13,179	
Foreign currency (gain) loss	(491)	667	903	(1,859)	1,886	8	(1,066)	(2,377)	(319)	-	
Deferred implementation costs	653	731	789	696	1,008	991	1,641	968	882	730	
Costs associated with financing events			123								
Loss on extinguishment of debt		23	28		-	-	53		-	-	
Restructuring costs					482	403	391	47			
Acquisition and integration costs									7,030	14,114	
Change in fair value of contingent consideration										1,480	
djusted EBITDA	(\$3,179)	(\$626)	\$2,967	\$6,891	(\$3,982)	(\$7,693)	(\$596)	\$4,491	(\$3,944)	(\$5,655)	
ridg Platform					-						
et (loss) income										(\$1,978)	
lust											
Depreciation and amortization expense										1,741	
Stock-based compensation expense										158	
Acquisition and integration costs										68	
djusted EBITDA										(\$11)	
Consolidated											
et (loss) income	(\$6,314)	(\$6,510)	(\$7,747)	\$3,427	(\$13,531)	(\$19,758)	(\$15,356)	(\$6,777)	(\$24,895)	(\$47,306)	
lus:											
Income tax benefit											
Interest expense (income), net	304	338	218	(312)	(284)	10	283	3,039	3,045	3,078	
Depreciation and amortization expense	961	1,053	1,167	1,354	2,331	1,545	1,933	2,017	3,065	8,833	
Stock-based compensation expense	1,708	3,072	7,486	3,585	4,126	9,108	11,578	7,584	7,248	13,337	
Foreign currency (gain) loss	(491)	667	903	(1,859)	1,886	8	(1,066)	(2,377)	(319)		
Deferred implementation costs	653	731	789	696	1,008	991	1,641	958	882	730	
Costs associated with financing events			123								
Loss on extinguishment of debt		23	28								
Restructuring costs		-			482	403	391	47			
Acquisition and integration costs									7,030	14,182	
Change in fair value of contingent consideration										1,480	
diusted EBITDA	(\$3.179)	(\$626)	\$2,967	\$6.891	(\$3,982)	(\$7,693)	(\$596)	\$4,491	(\$3,944)	(\$5,666)	



Reconciliation of GAAP Net Loss to Non-GAAP Net Loss and Non-GAAP Net Loss Per Share

(Amounts in thousands, except per share amounts)

		Three Months Ended June 30,		Six Months Ended June 30,	
	2021	2020	2021	2020	
Net loss	(\$47,306)	(\$19,758)	(\$72,201)	(\$33,289)	
Plus:					
Stock-based compensation expense	13,337	9,108	20,585	13,233	
Foreign currency loss	(2)	8	(319)	1,894	
Acquisition and integration costs	14,182	-	21,212	-	
Amortization of acquired intantibles	5,522	10	6,511	1,53	
Change in fair value of contingent consideration	1,480	-	1,480	-	
Restructuring costs		403	- 4	885	
Non-GAAP net loss	(\$12,785)	(\$10,239)	(\$22,732)	(\$17,277)	
Weighted-average number of shares of common stock used in computing non-GAAP net loss per share:		08			
Weighted-average common shares outstanding, diluted	32,977	27,072	31,145	26,898	
Non-GAAP net loss per share attributable to common stockholders, diluted	(\$0.39)	(\$0.38)	(\$0.73)	(\$0.64)	



Reconcilation of Forecasted GAAP Revenue to Billings

 Consumer Incentives
 \$28.0 - \$29.0

 Billings
 \$85.0 - \$95.0



Definitions

Adjusted contribution: We define adjusted contribution measures of the degree by which revenue generated from our marketers exceeds the cost to obtain the purchase data and the digital advertising space from our partners. Adjusted contribution demonstrates how incremental marketing spend on our platform amounts to support our sales and marketing, research and development, general and administration and other investments. Adjusted contribution is calculated by taking our total revenue less our Partner Share and other third-party costs exclusive of deferred implementation costs, which is a non-cash cost. Adjusted contribution does not take into account all costs associated with generating revenue from advertising campaigns, including sales and marketing expenses, research and development expenses, general and administrativities expenses and other expenses, which we do not take into consideration when making decisions on how to manage our advertising campaigns.

Adjusted EBITDA: We define adjusted EBITDA as our net loss before income tax benefit; interest expense, net; depreciation and amortization expense; stock-based compensation expense; foreign currency gain (loss); deferred implementation costs; restructuring costs; acquisition and integration costs; and change in fair value of contingent considerations.

ARR: We define ARR as the annualized GAAP revenue of the final month in the period presented for the Bridg platform. ARR should not be considered in isolation from, or as an alternative to, revenue prepared in accordance with GAAP. We believe that ARR is an indicator of the Bridg platform's ability to generate future revenue from existing clients.

ARPU: We define ARPU as the total Cardlytics platform revenue generated in the applicable period calculated in accordance with GAAP, divided by the average number of MAUs in the applicable period.

Billings: Billings represents the gross amount billed to customers and marketers for advertising campaigns in order to generate revenue. Cardlytics platform billings is recognized gross of both Consumer Incentives and Partner Share. Cardlytics platform GAAP revenue is recognized net of Consumer Incentives and gross of Partner Share. Bridg platform billings is the same as Bridg platform GAAP revenue.

Campaign spend ratio: We define campaign spend ratio as the amount of spend from MAUs that is associated with the campaigns in which they were targeted with offers divided by the total amount of spend from MAUs in the industries in which MAUs were targeted with offers during the applicable period.

MAUs: We define MAUs as targetable customers or accounts that have logged in and visited online or mobile applications containing offers from, opened an email containing offers from, or redeemed an offer from the Cardlytics platform during a monthly period. We then calculate a monthly average of these MAUs for the periods presented.

Monthly log-in days: We define monthly log-in days as the number of days in which MAUs logged in and visited the online or mobile banking applications of, or opened an email containing our offers from, our partners during a monthly period. We then calculate an average of the monthly log-in days for the periods presented.

Non-GAAP net loss: We define non-GAAP net loss as our net loss income before stock-based compensation expense; foreign currency (gain) loss; acquisition and integration costs; amortization of acquired intengibles; change in fair value of contingent considerations; and restructuring costs. Notably, any impacts related to minimum Partner Share commitments in connection with agreements with certain Partners are not added back to net loss in order to calculate adjusted EBITO.

Non-GAAP net loss per share: We define non-GAAP net loss per share as non-GAAP net loss divided by GAAP weighted-average common shares outstanding, diluted.

Offer activation rate: We define offer activation rate as the total number of offers activated by MAUs divided by the total number of offers served to MAUs in the applicable period.



Industry Definitions

Segment Families Industry DTC Direct to consumer

Entertainment Amusement Parks, Cinema/Video, Concerts/Theater, Gaming, Golf, Miscellaneous Recreation Services, Museums/Parks, Radio, Sporting & Sporting Venues/Other, Ticket Providers

Grocery Convenience, Grocery

Other Business Services, Financial Institutions, Gyms/Fitness, Home/ Maintenance, Online Education/ Distance Learning, Other Services, Salon/Spa

Banquet/Caterers, Bars/Night Clubs/Taverns, Fast Food/ Quick Serve, Full Service Restaurants, Quick Serve Light Fares

Accessories, Apparel, Auto Services and Products, Beauty Products/Cosmetics, Books/ Magazine, Child/ Infant Care, Drug Store/Pharmacy, General/Multi-Line, Home & Garden, Office Supplies, Other Retail, Pets, Shoes & Athletic Footwear, Specialty Gifts, Sporting & Outdoor Goods Retail

Bundled, Insurance/Real Estate, Internet, Phone, Professional Services, Television

Airlines, Car Rental, Cruise Lines, Gas Stations, Hotels/Lodging, Other Travel, Parking Services, Personal Transportation, Tour Operators/Agencies, Travel Aggregators and Agencies Travel

Antique/Pawn, Charitable and Social Service Organizations, Courier/Freight/Storage, Gambling, Government, Lifestyle/ Social, Medical Services, Other Educational, Schools Exclusions



